Abstract
Dacarbazine is widely used in the systemic treatment of malignant melanoma and Hodgkin's disease. While side effects of nausea, vomiting, and bone marrow depression are well recognized, adverse skin reactions are less common. We report a localized skin reaction to the intravenous (IV) administration of dacarbazine that histologically resembled a fixed drug reaction. Report of a Case A 19-year-old man was hospitalized in September 1980 for recurrent Hodgkin's disease, manifested by severe peripheral lymphadenopathy. In the hospital he began treatment on a regimen of mechlorethamine hydrochloride, procarbazine hydrochloride, prednisone, doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, and dacarbazine chemotherapy. He had previously been treated with mechlorethamine, vincristine, prednisone, and procarbazine chemotherapy, which had produced a complete remission, but paralytic ileus had developed secondary to vincristine-caused autonomic neuropathy. He had never received dacarbazine before September 1980. Four hundred milligrams of dacarbazine, diluted in 1 dL of a 5% glucose-and-water solution, was
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.